Pipeline And Commercial Insight Urinary Incontinence Provides An Overview Of Key Marketed Brands Late And Early Stage Pipeline Drugs And Cell Therapies
Posted on: Monday, 4 February 2008, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c81681) has announced the addition of "Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth" to their offering.
The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSKs Vesicare (solifenacin), and Novartis Enablex (darifenacin).
Scope
Analysis of patient potential, unmet needs and clinical trial design in UI.
Overview of key marketed brands, late- and early-stage pipeline drugs, and cell therapies.
Indication-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs.
Identification of future market events that are expected to affect UI drug revenues.
Highlights of this title
Pfizer's Detrol LA (tolterodine) will remain the market leading UI brand through to 2012 when it comes off patent. At this point Detrol LA will be followed by the other second generation anticholinergics, GSKs Vesicare (solifenacin), Novartis Enablex (darifenacin) and Pfizers chemical reformulation Toviaz (fesoterodine).
Following the patent expiry of the key brands, Detrol LA in 2012, and Enablex/Vesicare in 2015, a novel mechanism of action is required for long-term market growth. Examples of the possible mechanisms of action include the NK-1 antagonists and the adrenergic modulators.
We have identified a great untapped patient base in the US stress urinary incontinence (SUI) market. A drug that could come into this market would benefit from exclusivity, being the only treatment approved for SUI in the US with a potential 28 million patient base.
Key reasons to purchase this title
Benchmark key late-stage UI pipeline compounds against current market leading brands.
Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the UI market based on key opinion leader comments.
Contents:
About Us Healthcare
Chapter 1. Executive Summary
Chapter 2. Market Overview And Potential
Chapter 3. Brand Dynamics And Leading Comparator Therapies
Chapter 4. Forecast Analysis
Chapter 5. Global Opportunities And Threats
Chapter 6. Pipeline Overview - R&D Dynamics And Approach
Chapter 7. Late-Stage Drug Analysis & Forecasts
Chapter 8. Early-Stage Projects
Bibliography
Appendix
List of Tables
List of Figures
For more information visit http://www.researchandmarkets.com/reports/c81681
Source: Datamonitor
Source: Business Wire
Related Articles
- Invizion Selects Q2 Marketing for Strategic Messaging and Branding
- Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
- Gap Inc. Outlines Business Strategies for Brands and Highlights Growth Opportunities in Online and International Categories
- Get a Deep Insight into The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)
- Research and Markets: The Buckeye Partners, L.P., Pipeline Operations Asset Summary Report Examines Its Key Business Structure and Operations, History and Products
- Research and Markets: Equitable Resources Inc. Pipeline Operation Asset Summary Report Provides Summary Analysis of Its Key Revenue Lines and Strategy
- Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference
- Kronos Foods Appoints Two Top Executives; Leading Greek Foods Manufacturer to Focus on Brand Innovation and Growth
- Welsh Pupils' Key Stage Assessments Improve
 |
 |
User Comments (0)
RSS Feeds